The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - Asahi Kasei; AstraZeneca; Chugai Pharma; MSD
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst)
 
Tatsushi Kobayashi
Research Funding - CANON MEDICAL SYTEMS (Inst)
 
Yasutoshi Kimura
No Relationships to Disclose
 
Soichiro Morinaga
No Relationships to Disclose
 
Hirochika Toyama
No Relationships to Disclose
 
Teiichi Sugiura
No Relationships to Disclose
 
Satoshi Hirano
No Relationships to Disclose
 
Yasuhiro Shimizu
No Relationships to Disclose
 
Moriaki Tomikawa
No Relationships to Disclose
 
Hiroshi Sadamori
No Relationships to Disclose
 
Akio Katanuma
No Relationships to Disclose
 
Yoshiki Horie
No Relationships to Disclose
 
Michiaki Unno
Honoraria - AstraZeneca; Incyte Japan; Miyarisan pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Sonire Therapeutics
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Keishi Sugimachi
No Relationships to Disclose
 
Hironori Yamaguchi
No Relationships to Disclose
 
Motohiro Kojima
No Relationships to Disclose
 
Tetsuo Akimoto
No Relationships to Disclose
 
Katsuhiko Uesaka
No Relationships to Disclose
 
Shinichiro Takahashi
Honoraria - Taiho Pharmaceutical; Viatris